KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) EBITDA Margin (2020 - 2025)

Ginkgo Bioworks Holdings filings provide 6 years of EBITDA Margin readings, the most recent being 242.23% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 773.0% to 242.23% in Q4 2025 year-over-year; TTM through Dec 2025 was 181.66%, a 6072.0% increase, with the full-year FY2025 number at 181.66%, up 6072.0% from a year prior.
  • EBITDA Margin hit 242.23% in Q4 2025 for Ginkgo Bioworks Holdings, down from 207.05% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 34.37% in Q3 2021 to a low of 1134.55% in Q4 2021.
  • Median EBITDA Margin over the past 5 years was 246.1% (2025), compared with a mean of 348.84%.
  • The widest YoY moves for EBITDA Margin: up 96382bps in 2022, down -97853bps in 2022.
  • Ginkgo Bioworks Holdings' EBITDA Margin stood at 1134.55% in 2021, then skyrocketed by 85bps to 170.73% in 2022, then plummeted by -249bps to 596.49% in 2023, then skyrocketed by 58bps to 249.97% in 2024, then rose by 3bps to 242.23% in 2025.
  • The last three reported values for EBITDA Margin were 242.23% (Q4 2025), 207.05% (Q3 2025), and 116.52% (Q2 2025) per Business Quant data.